The goal of the ONCOVALUE project is to increase the ability of European cancer hospitals to collect real-world data (RWD) easily and in a timely manner. Systematic collection and analysis of clinical data is needed for continuous development of treatment and improvement of results. Real-time, high-quality clinical data also supports regulatory and health impact assessment bodies’ decision-making on the value of new cancer treatments. At best, the ONCOVALUE project can also promote the introduction of effective new treatments. In addition, RWD allows the identification of groups of patients who will not benefit from a given treatment, helping to target treatments to patients with a favorable response.
Consortium partners are working to develop new AI-based tools to automate clinical data collection and analytics. In addition, an end-to-end infrastructure will be built for RWD reporting in healthcare regulation and HTA decision-making. In addition, ONCOVALUE ensures the implementation of the developed guidelines and methods by providing training on 1) the collection and management of high-quality RWD in European cancer centers and 2) the analysis of these data by HTA and regulatory bodies.
By opening the door to widespread RWD regulatory and HTA integration, ONCOVALUE will lead to safer, more effective and affordable treatments, technologies and digital solutions for (personalized) cancer care. As such, ONCOVALUE is able to promote the cost-effectiveness and sustainability of cancer treatment. Systematic collection and evaluation of patient-reported results also leads to improved patient well-being. Subsequently, the long-term implementation of value-based cancer care in European cancer hospitals will help reduce the growing burden of cancer care in the EU and worldwide.
The consortium consists of several leading European cancer hospitals and industry partners specializing in artificial intelligence, machine learning and communication. The preparation of the proposal was supported by Ttopstart, a consulting company specializing in EU funding.
ONCOVALUE consortium: HUS Helsinki University Hospital (FI), Stichting Het Nederlands Kanker Instituut-Anton (NL), Elevate BV (NL), IQVIA Solutions BV (NL), Rigshospitalet Copenhagen University Hospital (DK), BC Platforms LTD OY (FI ) ), Siemens Healthcare GMBH (GER), Instituto Portugues de Oncologia do Porto (PT), Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” (IT), CIAOTech Srl (IT), TTOPSTART BV (NL).
Source: Helsinki University Hospital (HUS)
Source: The Nordic Page